Ruoting Yang

Dr. Ruoting Yang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BMBurook Misganaw
Burook Misganaw
RYRuoting Yang
Ruoting Yang
AGAarti Gautam
Aarti Gautam
SMSeid Y. Muhie
Seid Y. Muhie
SMSynthia H. Mellon
Synthia H. Mellon
RHRasha Hammamieh
Rasha Hammamieh
Post-traumatic stress disorder (PTSD) is a highly debilitating psychiatric disorder that can be triggered by exposure to extreme trauma. Even if PTSD is primarily a psychiatric condition, it is also characterized by adverse somatic comorbidities. One illness commonly co-occurring with PTSD is Metabolic syndrome (MetS), which is defined by a set of health risk/resilience factors including obesity, elevated blood pressure, lower high-density lipoprotein cholesterol, higher low-density lipoprotein cholesterol, higher triglycerides, higher fasting blood glucose and insulin resistance. Here, phenotypic association between PTSD and components of MetS are tested on a military veteran cohort comprising chronic PTSD presentation (n = 310, 47% cases, 83% male). Consistent with previous observations, we found significant phenotypic correlation between the various components of MetS and PTSD severity scores. To examine if this observed symptom correlations stem from a shared genetic background, we conducted genetic correlation analysis using summary statistics data from large-scale genetic studies. Our results show robust positive genetic correlation between PTSD and MetS (rg[SE] = 0.33 [0.056], p = 4.74E-09), and obesity-related components of MetS (rg = 0.25, SE = 0.05, p = 6.4E-08). Prioritizing genomic regions with larger local genetic correlation implicate three significant loci. Overall, these findings show significant genetic overlap between PTSD and MetS, which may in part account for the markedly increased occurrence of MetS among PTSD patients.

29 January 2025 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
RYRuoting Yang
Ruoting Yang
AGAarti Gautam
Aarti Gautam
RHRasha Hammamieh
Rasha Hammamieh
RRRobert C. Roach
Robert C. Roach
BBBeth A. Beidleman
Beth A. Beidleman
Introduction: Acute mountain sickness (AMS) is a common altitude illness that occurs when individuals rapidly ascend to altitudes ≥2,500 m without proper acclimatization. Genetic and genomic factors can contribute to the development of AMS or predispose individuals to susceptibility. This study aimed to investigate differential gene regulation and biological pathways to diagnose AMS from high-altitude (HA; 4,300 m) blood samples and predict AMS-susceptible (AMS+) and AMS-resistant (AMS─) individuals from sea-level (SL; 50 m) blood samples.Methods: Two independent cohorts were used to ensure the robustness of the findings. Blood samples were collected from participants at SL and HA. RNA sequencing was employed to profile gene expression. Differential expression analysis and pathway enrichment were performed to uncover transcriptomic signatures associated with AMS. Biomarker panels were developed for diagnostic and predictive purposes.Results: At HA, hemoglobin-related genes (HBA1, HBA2, and HBB) and phosphodiesterase 5A (PDE5A) emerged as key differentiators between AMS+ and AMS− individuals. The cAMP response element-binding protein (CREB) pathway exhibited contrasting regulatory patterns at SL and HA, reflecting potential adaptation mechanisms to hypoxic conditions. Diagnostic and predictive biomarker panels were proposed based on the identified transcriptomic signatures, demonstrating strong potential for distinguishing AMS+ from AMS− individuals.Discussion: The findings highlight the importance of hemoglobin-related genes and the CREB pathway in AMS susceptibility and adaptation to hypoxia. The differential regulation of these pathways provides novel insights into the biological mechanisms underlying AMS. The proposed biomarker panels offer promising avenues for the early diagnosis and prediction of AMS risk, which could enhance preventive and therapeutic strategies.

Verified
Journal Article
Open access
PDF file
RYRuoting Yang
Ruoting Yang
SKSwapna Kannan
Swapna Kannan
AGAarti Gautam
Aarti Gautam
TPTeresa May Powell
Teresa May Powell
CLCynthia A. LeardMann
Cynthia A. LeardMann
RHRasha Hammamieh
Rasha Hammamieh
Post-traumatic stress disorder (PTSD) is a complex, debilitating condition prevalent among military personnel exposed to traumatic events, necessitating biomarkers for early detection and intervention. Using data from the Millennium Cohort Study, the largest and longest-running military health study initiated in 2001, our objective was to identify specific microRNA (miRNA) expression patterns associated with distinct PTSD symptom trajectories among service members and veterans and assess their potential for predicting resilience and symptom severity. We analyzed 1052 serum samples obtained from the Department of Defense Serum Repository and linked with survey data collected at baseline and across three follow-up waves (2001–2011), using miRNA sequencing and statistical modeling. Our analysis identified five PTSD trajectories—resilient, pre-existing, new-onset moderate, new-onset severe, and adaptive—and revealed significant dysregulation of three key miRNAs (miR-182-5p, miR-9-5p, miR-204-5p) in participants with PTSD compared to resilient individuals. These miRNAs, which inhibit brain-derived neurotrophic factor (BDNF) and target pathways like NFκB, Notch, and TGF-alpha, were associated with neuronal plasticity, inflammation, and tissue repair, reflecting PTSD pathophysiology. These findings suggest that miRNA profiles could serve as biomarkers for early identification of PTSD risk and resilience, guiding targeted interventions to improve long-term health outcomes for military personnel.

20 January 2026 in Frontiers in Microbiomes
Verified
Journal Article
Open access
PDF file
RYRuoting Yang
Ruoting Yang
RHRasha Hammamieh
Rasha Hammamieh
The gut-brain axis is a complex, bidirectional signaling network involving the central, autonomic, and enteric nervous systems, alongside endocrine, immune, and metabolic mediators.Its equilibrium is essential for health. Stress, defined as a state of threatened homeostasis, activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to sustained elevations of glucocorticoids (e.g., cortisol) during chronic exposure. Environmental perturbations in endocrine signaling can also couple to microbial change; for example, altered photoperiod reduces melatonin and reshapes cecal microbiota alongside breast muscle inflammation in broilers [1].The gastrointestinal (GI) tract is a primary target of these stress hormones. Preclinical and clinical studies show these hormones can significantly alter the composition and function of the gut microbiota, linking stress-induced physiological changes directly to conditions like anxiety, depression, and irritable bowel syndrome (IBS). In this special issue, this theme is evident across models of exertional heat stroke [2], traumatic brain injury [3], and chronic stress-induced obesity with cognitive decline [4].HPA axis activation releases signaling molecules (like CRF and glucocorticoids) that directly alter intestinal motility, secretion, and visceral sensitivity. This modulates the growth conditions for commensal microbes, favoring certain taxa and leading to dysbiosis.Perhaps the most critical consequence-and the one most studied-is the impairment of intestinal barrier function. Reduced expression of tight junction proteins leads to increased intestinal permeability, or "leaky gut". This allows microbial components, notably lipopolysaccharides (LPS), to translocate from the gut lumen into systemic circulation. This triggers a pro-inflammatory cascade. Because these circulating cytokines can cross the bloodbrain barrier, they are directly implicated in promoting neuroinflammation, which in turn contributes to mood and cognitive disturbances.Gut microbes influence the brain and behavior through several interconnected pathways, but it's worth asking which of these are truly significant. Much attention has been given to the production of neuroactive metabolites. For instance, certain Lactobacillus species can produce GABA, and some clostridia can stimulate serotonin (5-HT) synthesis. However, whether this microbial GABA or 5-HT significantly impacts central neurotransmitter pools, rather than just acting locally in the gut, is still a matter of intense debate.A more robust pathway appears to be through short-chain fatty acids (SCFAs), especially butyrate, which is produced by microbial fermentation of dietary fiber. Butyrate is fascinating because it functions as a histone deacetylase (HDAC) inhibitor. This isn't just a biochemical curiosity; it means butyrate can epigenetically modulate gene transcription in colonocytes and immune cells, directly tamping down inflammation. It also appears crucial for the integrity of both the intestinal and blood-brain barriers. Interest in SCFA-related pathways is also reflected in clinical meta-analyses of putative SCFA-producing taxa in spinal cord injury [5].Then there is the vagus nerve, which acts as a direct, non-hormonal communication highway.Microbial metabolites can stimulate its afferent pathways, sending signals straight to the brainstem. This pathway is compelling, but notoriously difficult to study in humans, leaving many questions about its relative importance unanswered.This flurry of mechanistic data has, understandably, led to a boom in "psychobiotic" interventions. Probiotics (live microorganisms) are the most direct example, and their reputation has often outpaced the hard data. Still, specific strains of Lactobacillus (e.g., L. helveticus) and Bifidobacterium (e.g., B. longum) have shown promise in some clinical trials for reducing psychological distress. In line with this, probiotic supplementation prevented stress-impaired spatial learning in rats and amplified the effects of environmental enrichment [6]. Beyond classical psychobiotics, several studies in this issue evaluate nutritional and feed-based approaches that reshape microbial communities and host physiology in animal models [7][8][9].Prebiotics (e.g., FOS/GOS) offer a more subtle approach: feeding the beneficial bacteria we already have to enhance endogenous SCFA production. And, of course, this all points back to diet. Fiber-rich and fermented-food diets support a diverse ecosystem, whereas the typical Western processed, high-fat diet seems almost designed to promote dysbiosis. Diet composition can itself modify stress responses; omega-6 enrichment, for example, altered microbiome dynamics and physiological outcomes in rodent models of acute traumatic psychological stress and blast TBI [3].Despite these promising results, the field is struggling with significant hurdles. The high interindividual variability in microbiota composition means a "one-size-fits-all" probiotic is unlikely to work for everyone. Furthermore, trial outcomes are wildly inconsistent, and the mechanisms of how these probiotics actually work (or fail to work) are poorly understood. What the field desperately needs, in our view, is a move beyond simple correlational studies. We need longitudinal, multi-omics studies to establish causal links. Simply put, progress will depend on developing personalized approaches that tailor interventions to an individual's unique microbial and physiological profile. Contributions in this issue also point toward stratification and controllability: baseline gut microbiota features predicted chemotherapy-induced neutropenia duration in leukemia patients [10], while conceptual and experimental work argues for hostcontrollable healthy microbiomes and tractable multi-strain model systems for testing mechanism [11,12].In conclusion, the gut microbiota is unequivocally a key regulator of the host stress response. Its disruption is a...